Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06531473 · ClinicalTrials.gov registry record · NA

Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures

A NA study of Urologic Diseases and Prostate Obstruction, sponsored by Northwestern University.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT06531473: Recruiting NA study of Urologic Diseases and Prostate Obstruction, sponsored by Northwestern University.

NCT06531473 is a NA study of Urologic Diseases and Prostate Obstruction that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 300 participants, above the 93-participant average among 11 other Urologic Diseases trials with a reported enrollment target (223% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06531473, a NA study of Urologic Diseases and Prostate Obstruction, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The primary aim is to assess the impact of laser setting frequency and wattage during holmium laser enucleation of the prostate. There is currently no gold-standard laser settings for HoLEP procedures. In the investigator's current high-volume practice, the following settings for enucleation are: 2j 50hz. These settings are conventional settings, but there is no literature to prove optimal laser settings. The investigators hypothesizes that utilization of higher laser settings may be associated with a clinically significant (defined as \> 10%) decrease in procedural time without any detrimental postoperative outcomes, and a utilization of lower laser settings may be associated with a clinically significant (defined as \>10%) reduction in postoperative irritative voiding symptoms without any detrimental postoperative outcomes.

Primary Outcome

Comparing operative outcomes between the 40 hz, 50 hz and 60 hz laser setting groups.

Interventions

  • PROCEDURE HoLEP

Study Locations (1)

Illinois

  • Northwestern Medicine - Chicago

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-03-04
Est. Completion 2026-08-30
Phase NA
Northwestern University

1,209 total trials

What NCT06531473 shows while recruiting

NCT06531473 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 93-participant average among 11 other Urologic Diseases trials with a reported enrollment target (223% higher).

The record links to 2 conditions, with Urologic Diseases appearing as the primary indexed condition, and to 1 intervention - of which HoLEP is the first listed.

NCT06531473 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT06531473 about?

NCT06531473 is a clinical study titled "Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures". The primary aim is to assess the impact of laser setting frequency and wattage during holmium laser enucleation of the prostate. There is currently no gold-standard laser settings for HoLEP procedures. In the investigator's current high-volume practice, the following settings for enucleation are: 2j...

What is the current status of trial NCT06531473?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-03-04. Estimated completion is 2026-08-30.

What conditions does trial NCT06531473 study?

This clinical trial studies the following conditions: Urologic Diseases, Prostate Obstruction.

What interventions are being tested in trial NCT06531473?

The interventions under investigation include: HoLEP (PROCEDURE).

Who is sponsoring clinical trial NCT06531473?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06531473 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urologic Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06531473's enrollment target sits among peer trials

300 2nd of 11 the highest of 11 other Urologic Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Urologic Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06531473, the US trial registry maintained by the National Library of Medicine. NCT06531473 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.